Occult hepatitis B virus infection in chronic hemodialysis patients in Korea.
ABSTRACT Occult HBV infection that is serum HBsAg negative but HBV DNA positive is thought to be a contributing factor to ongoing HBV transmission within hemodialysis units. In the present study, the prevalence of occult HBV infection was investigated in patients on chronic hemodialysis in Korea, an endemic region for HBV.
Eighty-three patients undergoing maintenance hemodialysis at Samsung Medical Center, Seoul, South Korea were included. Serum samples were obtained from all patients. Testing for HBsAg, anti-HBs and anti-HBc was performed by an electrochemiluminescence immunoassay. HBV DNA was detected by the nested PCR method.
Among the 83 patients, 4 (4.8%) were HBsAg positive and HBV DNA positive. The remaining 79 patients were confirmed HBsAg-negative/HBV DNA-negative. Thus, the prevalence of occult HBV infection was 0%. All of the HBsAg-positive patients were anti-HBs-negative/anti-HBc-positive. Of 79 HBsAg-negative patients, 58 (73.4%) were anti-HBs positive and 52 (65.8%) were anti-HBc positive.
The present study showed that the prevalence of occult HBV infection in chronic hemodialysis patients at our center in Korea was not increased compared to the rates of low endemic regions. Furthermore, occult HBV infection was not a contributing factor in HBV transmission in the hemodialysis unit studied.
- SourceAvailable from: hbi.ir[Show abstract] [Hide abstract]
ABSTRACT: Introduction and objective: Hepatitis B virus (HBV) is a member of Hepadnaviridae and a major causative agent of chronic and acute hepatitis, liver cirrhosis and hepatocellular carcinoma. Genotype determination of HBV is based on PCR-RFLP and sequencing of genome of the virus. The genotype formation is mainly due to mutations of HBV precore, S, and YMDD (tyrosine-methionine-aspartate-aspartate motif in the C domain of the HBV DNA polymerase gene) genome area. Moreover, some of the mutant HBV remains undetectable by serological tests (occult hepatitis). Since the genotypes of HBV and occult hepatitis B has not been studied in our area, this study was conducted to determine both occult hepatitis B infection and genotypes among hemodialysis patients.Materials and methods: Two hundred and fifty hemodialysis patients were selected in this study. The sera of the patients were collected and the extracted DNA was used as template of PCR to amplify a 479bp fragment of the viral genome. The PCR products were digested by Ava2 and Mbo1 restriction enzymes. Based on RFLP patterns, the genotypes were determined. The HBV markers including; HBV surface antigen (HBsAg), hepatitis Bc antibody (HBcIgG), hepatitis B virus e antigen (HBeAg) and hepatitis B virus e antibody (HBeAb) were carried out for all the patients by ELISA test.Results: Fifty (20%) out of 250 sera showed positive HBV by PCR. Out of the 50 positive cases for HBV, 46(92%) belonged to genotype D2 and 2(4%) cases of them were B6 genotype. Ten cases were positive for HBV by PCR test but negative by ELISA test (4% occult hepatitis). Conclusion: Prevalence of HBV infection was high among the dialysis patients (20%), and occult hepatitis B was 4% in these patients. The dominant genotype of HBV was D2 (92%) followed by genotypes B6 (4%) in hemodialysis patients.Jundishapur Journal of Microbiology 01/2011; · 0.78 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: We investigated the prevalence of occult hepatitis B virus (HBV) infection in Japanese chronic hemodialysis patients. Hemodialysis patients (n = 1041) were screened for occult HBV. The presence of hepatitis B surface antigen (HBsAg), hepatitis B surface antibody, and hepatitis B core antibody (anti-HBc) was determined by various chemiluminescent immunoassays. HBV-DNA was quantified in patients positive for anti-HBc using quantitative real-time polymerase chain reaction. Among the 1041 patients, six (0.6%) were HBsAg-positive and 218 (20.9%) were anti-HBc-positive. All HBsAg-positive patients also tested positive for the presence of HBV DNA. Of 212 HBsAg-negative and anti-HBc-positive patients, three were positive for HBV DNA. Our study showed that the prevalence of occult HBV infection in chronic hemodialysis patients from eastern Japan was 0.3%.Therapeutic apheresis and dialysis: official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 06/2013; 17(3):289-92. · 1.53 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: Hepatitis B virus (HBV) is the most common disease commuted through blood transfusion. Occult hepatitis B infection (OBI) is a form of the disease which does not present Hepatitis B surface antigens (HBsAg) in the serum of patients; however, HBV-DNA is detectable in the serum and hepatocytes of patients. OBI is an important risk factor to induce post transfusion hepatitis (PTH), cirrhosis, hepatocellular carcinoma (HCC) and reactivation of the HBV. Recently, several reports from various regions of the world have been published regarding PTH among blood recipients as well as HCC, and cirrhosis among patients who require permanent blood transfusion, including diseases such as hemophilia, hemodialysis and thalassemia. This form of the hepatitis also creates problems for individuals that are co-infected with other viruses such as HCV and HIV. To determine the prevalence of OBI among hemophilia, hemodialysis and thalassemia patients is important because it is a high risk factor for PTH, HCC and cirrhosis therefore, its detection is a critical strategy for most health care services. This review addresses recent information regarding prevalence of OBI in relation to the mentioned diseases. The data presented here was collected by searching the key words in Pubmed and Scopous databases. Our searching in the published papers revealed that OBI prevalence is frequent in patients receiving frequent blood transfusions. it seems that one of the main mechanisms for OBI transmission is most likely through infected blood and its component and evaluation of the prevalence of OBI in donors and patients, especially those with hemophilia and thalassemia should be foul considered.Hepatitis Monthly 05/2012; 12(5):315-9. · 1.25 Impact Factor